Clinic Events PET Scan 
AuntMinnie
MAY 31, 2024
PET imaging with nitrogen-13 (N-13) ammonia radiotracer can help predict major adverse cardiac events in patients with ischemic heart disease (IHD), according to a study published May 30 in Radiology: Cardiothoracic Imaging. Patients underwent the scans between January 2017 and January 2021.
Medical Xpress: Radiology
JULY 16, 2024
Amyloid PET scans provide in-vivo evidence of Alzheimer's disease (AD) pathology. However, due to their high cost and limited insurance coverage, they are not widely used in clinical settings outside of the VA Healthcare System.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
JUNE 30, 2024
Welcome to the 2002 edition of the Minnies, AuntMinnie.com’ s annual event to recognize the best of radiology! Mayo Clinic, Jacksonville, FL MOST SIGNIFICANT NEWS EVENT IN RADIOLOGY 1. Increased use of medical imaging by other specialties (turf battles) HOTTEST CLINICAL PROCEDURE 1. Hybrid CT/PET scanning 2.
Imaging Technology
MAY 31, 2023
CR and CNR demonstrated using clinical data with inserted lesions of known size, location, and contrast. Quantitation accuracy demonstrated using clinical data with inserted lesions of known size, location, and contrast (ground truth). Deep learning–based time-of-flight (ToF) image enhancement of non-ToF PET scans.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since the U.S. please insert video here.
Imaging Technology
MAY 30, 2023
This event marks a major milestone in the expansion of Blue Earth Diagnostics’ robust prostate cancer portfolio. All of us at Blue Earth Diagnostics want to express our sincere gratitude to the many patients, physicians, clinical trial sites and collaborators who have worked closely with us to progress POSLUMA.” Gauden , D.Phil.,
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since the U.S.
Expert insights. Personalized for you.
110 
Let's personalize your content